1-tert-butoxycarbonyl-4-(2-(benzyloxy)phenyl)piperazine | 444582-88-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-tert-butoxycarbonyl-4-(2-(benzyloxy)phenyl)piperazine
• 英文别名: Tert-butyl 4-(2-phenylmethoxyphenyl)piperazine-1-carboxylate
• CAS: 444582-88-1
• 化学式: C₂₂H₂₈N₂O₃
• 分子量: 368.476
• InChiKey: YWVPNIBMLWSLHK-UHFFFAOYSA-N

物化性质

• 沸点：
  504.6±50.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-tert-butoxycarbonyl-4-(2-(benzyloxy)phenyl)piperazine 在 18-冠醚-6 、 5% Pd(II)/C(eggshell) 、 氢气 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 22.0h， 生成
  参考文献：
  名称：

  Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

  摘要：

  A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled human tachykinin NK3 receptor (hNK3-R) is described. Preliminary profiling revealed poor plasma and metabolic stability for these structures in rodents. Further optimization efforts resulted in analogs with improved potency, stability, and pharmacokinetic properties as well as good brain permeability, for example, compounds 26 and 42. Unexpected cytotoxicity was observed in such N-Me pyrazole structures as compounds 41-42. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.033
• 作为产物：
  描述：

  1-(2-羟基苯基)哌嗪 在 碳酸氢钠 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-tert-butoxycarbonyl-4-(2-(benzyloxy)phenyl)piperazine
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

  摘要：

  The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (K-i = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (K-i = 6600 nM). Sulfonamide 39 (K-i = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (K-i = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (K-i = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.

  DOI：

  10.1021/jm0304109

文献信息

• [EN] THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS DESTINÉS AU TRAITEMENT D'UN CANCER CARACTÉRISÉ PAR UNE MUTATION IDH
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2011072174A1

  公开（公告）日：2011-06-16

  Compounds and compositions comprising compounds useful in the treatment of cancer are described herein. The compounds and compositions can be used to modulate an isocitrate dehydrogenase (IDH) mutant (e.g., IDHIm or IDH2m) having alpha hydroxyl neoactivity.

  本文描述了用于治疗癌症的化合物和组合物。这些化合物和组合物可用于调节具有α-羟基新活性的异柠檬酸脱氢酶（IDH）突变体（例如IDH1m或IDH2m）。
• Melanocortin receptor agonists
  申请人：——

  公开号：US20040092507A1

  公开（公告）日：2004-05-13

  The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction. 1

  本发明涉及公式（I）的黑色素皮质素受体激动剂，其在肥胖症、糖尿病和男性和/或女性性功能障碍的治疗中有用。
• 大环类化合物及其医药用途
  申请人：中国药科大学

  公开号：CN116003434A

  公开（公告）日：2023-04-25

  本发明公开了如式(I)所示的大环类化合物或其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体、代谢产物、代谢前体、前药或溶剂化物。本发明的大环类化合物或其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体可用于制备预防或治疗MC4R介导的代谢性疾病的药物。本发明还公开了大环类化合物在制备MC4R激动剂中的用途。
• PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1368340A1

  公开（公告）日：2003-12-10
• US7291619B2
  申请人：——

  公开号：US7291619B2

  公开（公告）日：2007-11-06